Reckitt Reports Third-Quarter Results

By Richa Naidu
LONDON (Reuters) – Reckitt reported a smaller than expected fall in third-quarter underlying sales on Wednesday, helped by more shoppers buying its health products, which include Nurofen painkillers and Strepsils lozenges.

Shares in the consumer goods group rose 2% in morning trading, with signs of improving volumes welcomed by investors after a difficult year.

The stock fell sharply earlier this year due to an internal investigation into its Middle Eastern business and its involvement in litigation surrounding an infant nutrition product made by its U.S.-based Mead Johnson business.

Reckitt said in July it was considering options for the nutrition business and that it would offload a portfolio of homecare brands by the end of 2025, planning to refocus on healthcare and hygiene.

> "We're reviewing the organisation," CEO Kris Licht told journalists on a call. "Surely that will result in changes to staffing levels and certain organisation structures will change."

Reckitt, which also owns the Dettol and Lysol cleaning brands, said it was on track to meet full-year targets.

Its quarterly like-for-like net sales fell 0.5%, ahead of the 1.7% decline analysts had expected in a company-supplied poll.

Price/mix, a metric that reflects how much Reckitt sold its products for, rose 0.9% while volumes declined 1.4%, weakened by Reckitt's nutrition business. Analysts expected the price/mix to rise by 1.4% and volumes to fall by 3.1%.

A roughly 14% sales volume decline in Reckitt's nutrition business was driven by "the combination of lapping high market shares experienced during the U.S. competitor supply shortage and the impact from the Mount Vernon tornado, which destroyed both finished goods and raw materials and impacted short-term supply to customers in the third quarter," the company said.

The unit earlier in the year suffered supply disruptions after a tornado damaged a third-party U.S. warehouse.

> "Reckitt's results were less bad than feared," Waverton Investment Management portfolio manager Tineke Frikkee said. "Litigation remains the main overhang as well as the uncertain cost-or-benefit of corporate restructuring expected towards the end of 2025."